Identification of serum microRNAs as potential biomarkers in Pompe disease
Objective To analyze the microRNA profile in serum of patients with Adult Onset Pompe disease (AOPD). Methods We analyzed the expression of 185 microRNAs in serum of 15 AOPD patients and five controls using microRNA PCR Panels. The expression levels of microRNAs that were deregulated were further st...
Saved in:
Published in | Annals of clinical and translational neurology Vol. 6; no. 7; pp. 1214 - 1224 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.07.2019
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
ISSN | 2328-9503 2328-9503 |
DOI | 10.1002/acn3.50800 |
Cover
Summary: | Objective
To analyze the microRNA profile in serum of patients with Adult Onset Pompe disease (AOPD).
Methods
We analyzed the expression of 185 microRNAs in serum of 15 AOPD patients and five controls using microRNA PCR Panels. The expression levels of microRNAs that were deregulated were further studied in 35 AOPD patients and 10 controls using Real‐Time PCR. Additionally, the skeletal muscle expression of microRNAs which showed significant increase levels in serum samples was also studied. Correlations between microRNA serum levels and muscle function test, spirometry, and quantitative muscle MRI were performed (these data correspond to the study NCT01914536 at ClinicalTrials.gov).
Results
We identified 14 microRNAs that showed different expression levels in serum samples of AOPD patients compared to controls. We validated these results in a larger cohort of patients and we found increased levels of three microRNAs, the so called dystromirs: miR‐1‐3p, miR‐133a‐3p, and miR‐206. These microRNAs are involved in muscle regeneration and the expression of these was increased in patients' muscle biopsies. Significant correlations between microRNA levels and muscle function test were found.
Interpretation
Serum expression levels of dystromirs may represent additional biomarkers for the follow‐up of AOPD patients. |
---|---|
Bibliography: | Funding information This study was supported by a grant from Sanofi‐Genzyme (GZ‐2015‐11342) to Dr. Gallardo and has been registered in Clinicaltrials.gov (identifier NCT03045042). These authors equally contributed to this work. The Spanish Pompe Study Group : Miguel Angel Barba‐Romero (Hospital General de Albacete, Albacete, Spain), Joseba Barcena (Hospital Universitario Cruces, Baracaldo, Spain), María Rosario Carzorla (Hospital Puerta de Hierro, Majadahonda, Spain), Carlota Creus (Hospital Virgen de las Nieves, Granada, Spain), Jaume Coll‐Cantí (Hospital Germans Tries i Pujol, Badalona, Spain), Noemí de Luna (Neuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Spain), Manuel Díaz (Hospital de Cabueñes, Gijón, Spain), Cristina Domínguez (Hospital 12 de Octubre, Madrid & Insituto de Investigación i+12, Madrid, Spain), Roberto Fernández Torrón (Hospital Universitario Donostia, Spain), María José García Antelo (Hospital Universitario A Coruña, A Coruña, Spain), Josep María Grau (Hospital Clínic, Barcelona, Spain), María Teresa Gómez Caravaca (Hospital de Córdoba, Spain), Juan Carlos León Hernández (Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain), Adolfo López de Munáin (Hospital Universitario Donostia, Spain), Francisco Antonio Martínez‐García (Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain), Yolanda Morgado (Hospital Universitario Virgen de Valme, Sevilla, Spain), Antonio Moreno (Hospital Universitario Morales Meseguer, Murcia, Spain), Germán Morís (Hospital Universitario de Asturias, Oviedo, Spain), Miguel Angel Muñoz‐Blanco (Hospital Gregorio Marañón, Madrid, Spain), Andres Nascimento (Hospital Virgen del Rocío, Sevilla, Spain), Carmen Paradas (Hospital Virgen del Rocío, Sevilla, Spain), José Luis Parajuá Pozo (Hospital de Can Mises, Ibiza, Spain), Luis Querol (Neuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Spain), Arturo Robledo‐Strauss (Hospital Juan Ramón Jiménez, Huelva, Spain), Ricard Rojas García (Neuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Íñigo Rojas‐Marcos (Hospital Virgen de Macarena, Sevilla, Spain), Jose Antonio Salazar (Hospital Regional Universitario de Málaga, Spain), Mercedes Usón (Hospital de Son Llátzer, Palma de Mallorca, Spain). Coinvestigators ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 Coinvestigators – The Spanish Pompe Study Group: Miguel Angel Barba‐Romero (Hospital General de Albacete, Albacete, Spain), Joseba Barcena (Hospital Universitario Cruces, Baracaldo, Spain), María Rosario Carzorla (Hospital Puerta de Hierro, Majadahonda, Spain), Carlota Creus (Hospital Virgen de las Nieves, Granada, Spain), Jaume Coll‐Cantí (Hospital Germans Tries i Pujol, Badalona, Spain), Noemí de Luna (Neuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Spain), Manuel Díaz (Hospital de Cabueñes, Gijón, Spain), Cristina Domínguez (Hospital 12 de Octubre, Madrid & Insituto de Investigación i+12, Madrid, Spain), Roberto Fernández Torrón (Hospital Universitario Donostia, Spain), María José García Antelo (Hospital Universitario A Coruña, A Coruña, Spain), Josep María Grau (Hospital Clínic, Barcelona, Spain), María Teresa Gómez Caravaca (Hospital de Córdoba, Spain), Juan Carlos León Hernández (Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain), Adolfo López de Munáin (Hospital Universitario Donostia, Spain), Francisco Antonio Martínez‐García (Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain), Yolanda Morgado (Hospital Universitario Virgen de Valme, Sevilla, Spain), Antonio Moreno (Hospital Universitario Morales Meseguer, Murcia, Spain), Germán Morís (Hospital Universitario de Asturias, Oviedo, Spain), Miguel Angel Muñoz‐Blanco (Hospital Gregorio Marañón, Madrid, Spain), Andres Nascimento (Hospital Virgen del Rocío, Sevilla, Spain), Carmen Paradas (Hospital Virgen del Rocío, Sevilla, Spain), José Luis Parajuá Pozo (Hospital de Can Mises, Ibiza, Spain), Luis Querol (Neuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Spain), Arturo Robledo‐Strauss (Hospital Juan Ramón Jiménez, Huelva, Spain), Ricard Rojas García (Neuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Íñigo Rojas‐Marcos (Hospital Virgen de Macarena, Sevilla, Spain), Jose Antonio Salazar (Hospital Regional Universitario de Málaga, Spain), Mercedes Usón (Hospital de Son Llátzer, Palma de Mallorca, Spain). |
ISSN: | 2328-9503 2328-9503 |
DOI: | 10.1002/acn3.50800 |